Home » Stocks » INFI

Infinity Pharmaceuticals, Inc. (INFI)

Stock Price: $2.69 USD -0.07 (-2.54%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Pre-market: $2.67 -0.02 (-0.74%) Mar 8, 5:25 AM
Market Cap 237.71M
Revenue (ttm) 1.59M
Net Income (ttm) -41.28M
Shares Out 60.51M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $2.69
Previous Close $2.76
Change ($) -0.07
Change (%) -2.54%
Day's Open 2.78
Day's Range 2.33 - 2.78
Day's Volume 2,881,294
52-Week Range 0.60 - 5.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 5 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, today announced that management will present at the H.C. Wainwright Gl...

24/7 Wall Street - 1 week ago

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CVE, ASC, CHRA, VTGN
The Motley Fool - 2 weeks ago

Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.

Other stocks mentioned: AMZN, BMY, GILD, NVAX, RHHBY, SHOP, TRIL, WMT
Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially firs...

Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially firs...

Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, an oral, immuno-on...

The Motley Fool - 3 weeks ago

The company reported results from a clinical study.

Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncol...

Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today presented data from MARIO-275 (MAcrophage Reprogramming in Immune Oncology)...

Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncol...

Benzinga - 1 month ago

Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmace...

Other stocks mentioned: BCLI, ORTX, VIVO
24/7 Wall Street - 1 month ago

With the trading day about halfway over, the broad markets were trading sideways into the weekend.

Other stocks mentioned: BIIB, FTNT, KSS, PINS, ARWR, DECK, IP, JAZZ, SNAP
Zacks Investment Research - 1 month ago

Does Infinity Pharmaceuticals (INFI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will participate in a Fireside Chat with Andrew D'Silva of B. Riley Securities on Wednesday, January 20, 2021 a...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting data from MARIO-275 on the first day of the American Society of Clinical Oncology (ASCO) 202...

Zacks Investment Research - 2 months ago

Infinity (INFI) provides an update on Eganelisib in patients with metastatic urothelial cancer.

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this m...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Company's randomized, placebo controlled Phase 2 study evaluating th...

Benzinga - 2 months ago

Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher on Wednesday after the company announced it has received CLIA Licensure from the State of California that permits testing of clin...

Other stocks mentioned: SRNE
Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that data from the front-line triple negative breast cancer (TNBC) cohort from the ongoing MARI...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoi...

Seeking Alpha - 3 months ago

Recent results pleased analysts. The company's relationship with various Big Pharma companies will be key to  future revenues and to the stock price.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in ...

Seeking Alpha - 3 months ago

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Infinity (INFI) delivered earnings and revenue surprises of -6.67% and 130.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2020 financial results and provided an update on the Company, including its t...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the presentation of data from the melanoma and squamous cell carcinoma of the head and neck (SC...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class immuno-oncology product candida...

Zacks Investment Research - 4 months ago

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 months ago

Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC ...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganeli...

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc.

Seeking Alpha - 7 months ago

Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Infinity (INFI) delivered earnings and revenue surprises of 20.00% and 80.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 7 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc.

Business Wire - 7 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc.

Zacks Investment Research - 8 months ago

Infinity (INFI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 8 months ago

Infinity (INFI) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.

Zacks Investment Research - 9 months ago

Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.

Seeking Alpha - 9 months ago

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Infinity (INFI) delivered earnings and revenue surprises of -111.11% and 74.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Infinity (INFI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 11 months ago

Infinity (INFI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 11 months ago

The FDA bestows a Fast Track designation on Infinity's (INFI) IPI-549 in combination with Opdivo for treating advanced urothelial cancer. Stock rise.

Benzinga - 11 months ago

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) shares are trading higher on Wednesday, after the company announced the FDA has granted fast track designation for IPI-549 in combination with niv...

Zacks Investment Research - 1 year ago

Infinity (INFI) posts a wider-than-expected loss for the fourth quarter of 2019.

Seeking Alpha - 1 year ago

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Infinity (INFI) delivered earnings and revenue surprises of -5.26% and 8.83%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

About INFI

Infinity Pharmaceuticals, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, I... [Read more...]

Industry
Biotechnology
CEO
Adelene Perkins
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
INFI
Full Company Profile

Financial Performance

In 2019, INFI's revenue was $3.05 million, a decrease of -86.23% compared to the previous year's $22.15 million. Losses were -$47.06 million, 318.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for INFI stock is "Buy." The 12-month stock price forecast is 7.60, which is an increase of 182.53% from the latest price.

Price Target
$7.60
(182.53% upside)
Analyst Consensus: Buy